INTRODUCTION
Leishmaniasis, caused by the protozoan parasite of the genus Leishmania, affects over 12 million individuals worldwide, 1.5 -2 million of whom develop symptomatic disease every year [1] . The parasite is spread by the sand fly vector and causes a spectrum of diseases depending on the parasite species and the host immune status. Clinical manifestations of the disease range from self-limiting cutaneous Leishmaniasis, disfiguring muco-cutaneous Leishmaniasis, to fatal visceral leishmaiasis. Current treatment use toxic antimonial compounds. These treatments are laborious and expensive, cause severe side effects and emerging drug resistance has been reported [2] . Therefore, an alternative effective treatment regime would be desirable.
Immunity against L. major infection is well characterized in the mouse model and depends mainly on T-helper1 (Th1) immune responses mediated by CD4 + T cells induced by the essential cytokine IL-12 [3] . As Leishmania reside within macrophages, they deviously manipulate the host innate and acquired immune mechanisms. This ensures their survival within the hostile environment of macrophages and hinges on their capacity to modulate macrophage effect or functions including production of reactive nitrogen intermediates, RNI [4] . Macrophages can induce host cells to produce cytokines that promote disease progression via regulation of Th1 and Th2 cells. The Th1 cells by secreting IFN-δ enhance macrophage microbial activity, thus protecting the host from intracellular Leishmania pathogens [5] . Conversely, the parasite for survival cleverly augments Th2 response, leading to an increased secretion of IL-4 and IL-10, resulting in attenuation of the host mechanisms and Leishmania infection ensues [6] .
Newly synthesized pyrimidine and pyrazolo derivatives are well documented [7, 8] . Hetero cyclic compounds exhibit anthelmintic, anti HIV activity and hypoglycemic activity [9] , antimicrobial, analgesic [10, 11] , against herpes simplex virus type-1 (HSV-1) and hepatitis-A virus (HAV), serotonin 5-HT6 receptor antagonist [12] , antitumor activity and anticancer activity [13] . Thiazolopyrimidines have hypoglycemic, hypolipidemic, anti-diabetic, [14] and antimalarial [15, 16] . As an extension of our ongoing studies, the objective of the present work is to synthesize new compounds and evaluates them both in vitro and in vivo for their anti-protozoal activities against experimental cutaneous Leishmaniasis in mice.
EXPERIMENTAL
In a previous work, we have reported the synthesis of substituted pyrazolopyrimidine 3 and pyrazolopyrazole 4 by using 1-(naphtho[1,2-d]thiazol-2-yl)hydrazine 1 as starting material. The starting material 1 was synthesized according to the previous procedure [17] (Scheme 1).
The reaction of compound 1 with ethoxymethylene malomonitrile afforded the corresponding 3-amino-4-cyanopyrazolo derivatives 2, which was treated with formamide or hydrazine hydrate to produce the corresponding 3-aminopyrazolopyrimidine 3 and aminopyrazolopyrazole derivative 4, respectively [18] (Scheme 2). 19) corresponding to the molecular formula C 16 H 10 N 6 S and at 120 (100, base peak).
Synthesis of 2-[5-amino-3H-pyrazolo[3,4-c]pyrazol-2-yl]naphthalino[1,2-d]thiazole (4)
A mixture of compound 2 (0.01 mol), and hydrazine hydrate (0.01 mol) in acetic acid (30 mL) was refluxed for 3 h. The reaction mixture was poured onto ice cold water. The solid was filtered off, dried and crystallized from ethanol to give title product 4 as green powder. Yield 69 %; mp > 300 °C; IR (KBr, cm 
Animals
Five to 6-week-old BALB/c mice of either sex, 16-18 g each were purchased from Theodor Bilharz Research Institute TBRI, Egypt. Approval of the institutional Animal Ethical Committee for the animal studies was obtained from the Office of Environmental Health and Radiation Safety (ACUC protocol # 1096-5). The animals were maintained according to accepted standards of human care [19] 
Parasite culture
Promastigotes from Indian Leishmania donovani isolate (NS2) were routinely passaged in mice and after transformation, cultured at 24 o C in medium 199 supplemented with 10 % heat inactivated fetal calf serum (HIFCS), Penicillin G (50 IU/mL) and Streptomycin (50 µg/mL). For infection of macrophages, 24 h prior to the experiment, stationary phase promastigotes were centrifuged and the pellet re-suspended in Schneider's insect medium supplemented with 20 % HIFCS, pH 5.5, as described by [20] In vitro anti-amastigote activity in macrophages Peritoneal macrophages lavaged from BALB/c mice were seeded in 16 chamber slides (1. After removal of non-internalized parasite, macrophages were then co-cultured with the above mentioned supernatants in the presence or absence of compound 3 and compound 4 separately at a dose of (0 -25 µM) for 72 h, after which cells were fixed., Giemsa-stained (diluted 1:7 in deionized water, pH 6.8) and examined microscopically for intracellular amastigotes. At least 100 macrophages/well were counted to calculate the percentage of infected macrophages. The infection rate of treated macrophages was normalized to 100 % for further analysis.
Safety index of the synthetic compounds
To investigate the cytotoxicity of the compounds, murine macrophages (1.5 x 10 5 /200 µl/well) were incubated with the compounds (0 -100 µM) at 37 o C, 5 % CO 2 for 48, 72 and 96 h and cell viability enumerated as described by [21] . The safety index was calculated as the IC 50 of the compound in macrophages/ IC 50 of compound in amastigotes.
Reverse transcriptase polymerase Chain reaction (RT-PCR)
Total RNA was isolated using the RNAqueous Kit from normal and Leishmania-infected macrophages (obtained from BALB/c mice) after being treated the tested compound (2.5 and 10 µM) for 18 h. Subsequently, RT-PCR was carried out with the one-step RT-PCR kit using (200 ng/reaction) that was reverse-transcribed into cDNA and amplified, using gene-specific primers as described previously [22] .
IL-10 and IL-12 measurement using sandwich ELISA
Levels of mouse IL-10 and IL-12p40 present in the supernatants of uninfected and L. donovani infected macrophages that had been treated with the compounds for 24 h were measured using an ELISA kit as per the manufacturer's instruction. A standard curve with a cytokine-positive control was run in each assay, the lower limit of detection being 31.24 pg/mL for IL-10 and 15.0 pg/mL for IL-12p40.
Parasite Infection and tissue studies
Mice were inoculated in one hind footpad with metacyclic promastigotes. A total of 1-2 x 10 5 highly infective stage metacyclic promastigotes was isolated from stationary culture (5-7 d old) by negative selection using peanut agglutinin (Vector laboratories, Burlingame, CA) and injected subcutaneously in the left footpad. The infected footpad was kept under observation 16 weeks after infection for redness, swelling, ulceration, crust formation or gangrenous changes. The evolution of the lesion was monitored weekly by measuring footpad thickness using metric caliper (Mitutoyo Measuring Instruments, Aurora, IL). The degree of infection in parasitized footpad lesions was determined by limiting dilution analysis of homogenized tissue. To determine parasite concentrations, footpads were weighed and homogenized. Two-fold serial dilutions of the homogenized tissue suspensions were then plated in 96-well plates and incubated at 26 o C for 7-10 days. Wells were examined for viable and motile promastigotes, and the highest dilution that was positive for parasites was considered to be the parasite concentration per milligram of tissue. The total parasite burden was calculated using the weight of the footpad, as previously described [23] . 
Animal's treatment regime

Statistical analysis
The results are expressed as mean± SD/SEM as indicated. Statistical analysis was based on oneway ANOVA followed by Turkey's Multiple Comparison Test using Graph Pad Prism software, version 4. P < 0.05 was considered as statistically significant.
RESULTS
Anti-leishmanial activity of the synthesized compounds
The anti-leishmanial activity of the synthetic compounds (0 -25 µM) was evaluated in terms of the intracellular parasite load, wherein the infection rate of Leishmania infected macrophages was normalized to 100 %; with the addition of the tested compound, a dose dependent reduction in parasitic load was evident, the IC 50 being 2.5 µM (Fig. 1) . In macrophages, 92 % were parasitized and the average number of amastigotes/macrophage was 11.3. After treatment with the tested compound (72 h), the percentage of infected macrophages decreased in a dose-dependent manner. With 10 µM of the compound, only 59 % of macrophages were infected, the number of amastigotes/macrophage being 1.7. In uninfected macrophages, the tested compound (2.5 and 10 µM) induced an increase in mRNA expression of IL-12p40. Following infection with Leishmania parasites (as confirmed by Giemsa staining), a down regulation in mRNA expression of IL-12p40 was observed, which was reversed by the tested compound (Fig. 2) . This genetic up-regulation of IL-12p40 by the tested compound was correlated by quantifying levels in culture supernatants by ELISA. In uninfected macrophages, the mean ± SEM was 495.00 ± 26.53 pg/mL, which with the tested compound (2.5 and 10 µM) significantly increased by 1.85 and 1.9 fold (p < 0.001) respectively. Following successful intracellular Leishmania infection, levels of IL-12 reduced significantly by 1.7 fold, (p < 0.001), importantly, treatment with the synthetic compound (2.5 and 10 µM) significantly increased production of IL12p40 to 550.8 ± 60.5 (p < 0.05) and 595.1 ± 32.98 pg/mL (p < 0.01) respectively compared with infected macrophages (Fig. 3) .The tested compound (2.5 and 10 µM), significantly decreased the secretion of IL-10 as compared with the infected macrophages (data not shown). Early onset was observed in the infected control group (GP1), where swelling, ulceration and gangrene formation were observed in the majority of mice and the lesion developed up to total gangrene and auto-amputation. Later onset was observed in the reference drug treated group (GP2), up to ulceration with minority of mice developed gangrene and only 2 mice developed auto-amputation. Also, the latest onset was observed in the compound 4 treated group (GP3) and the combination treated group (GP4) up to ulceration with no gangrene or amputation, where the ulcers were slow developing, healing and only observed in the minority of mice as shown in (Table 1 ). There was a dramatic lessening of disease progression, as seen by reduction of footpad swelling in mice treated with the compound 4 combined with IL-12 compared with the infected control group, (data not shown).
DISCUSSION
In a previous work, we have reported the synthesis of pyrazolopyrimidine and pyrazolopyrazole derivatives using hydrazinothiazole 1 as starting material. The reaction of α-amino naphthol with KSCN produced 2 amino thiazolo derivatives. The reaction of 2-amino thiazolo derivatives with sodium nitrite and hydrochloric acid produced the corresponding diazoium salt, which converted to 2-hydrazine thiazolo derivatives 1 (Scheme 1). Reaction of hydrazinothiazolo derivatives 1 with ethoxymethylene afforded compound 2, which reacted to formamide and hydrazine hydrate respectively to produce pyrazolopyrimidine 3 and pyrazolopyrazole 4 respectively (Scheme 2). All the synthesized compounds were confirmed by spectral data (IR, We initially investigated whether the new synthetic compounds 3 and 4 affect the amastigote activity inside Leishmania infected macrophages and affect the IL-12 mRNA gene expression with IL-10, IL-12 cytokines secretion levels. In uninfected macrophages, the tested compounds (2.5 and 10 µM) induced an increase of IL-12p40 mRNA gene expression. Following infection with Leishmania parasite a downregulation of this protein was observed, which was reversed by our new synthetic compounds. This genetic up-regulation was correlated with the increased levels of IL-12 after treatment of infected macrophages with the compounds.
Animal studies showed that compound 4 treated group (GP3) achieved a maximum delayed onset of cutaneous Leishmaniasis disease progression with a decrease of footpad thickness and parasite density in the infected footpad compared with the infected control group (GP1), specifically when combined with the immunotherapeutic agent IL-12 (GP4). Our results showed the antileishmanial activity of the synthetic compounds were in consistence with previous results showed that hetero-cyclic compounds were potent anthelmintic, anti-fungal and anti-malarial agents [10] [11] [12] [13] [14] [15] [16] 
CONCLUSION
The results indicate that the synthesized heterocyclic organic compounds, a new series of substituted pyrazolopyrimidine 3 and pyrazolopyrazole 4, are promising agents for the development of new antiprotozoal candidates for enhanced safety and pharmacological efficacy when augmented with immunotherapy IL-12 for the treatment of cutaneous leishmaniasis. 
